MRI-PDFF相对下降30%预测NAFLD纤维化逆转的临床效用
这项前瞻性研究纳入100例经活检证实NAFLD且有两个时间点配对MRI-PDFF评估的患者,定义MRI-PDFF应答为相对下降≥30%,主要结局为纤维化分期逆转≥1期。多变量校正分析显示MRI-PDFF应答是纤维化逆转的独立预测因子(校正OR 6.46,95%CI 1.1-37.0,p=0.04),可用于早期试验中估计纤维化改善的几率及样本量估算。
要点
- MRI-PDFF相对下降≥30%与NAFLD患者纤维化逆转≥1期独立相关(校正OR 6.46)。
- MRI-PDFF应答者中纤维化逆转、无变化和进展的比例分别为40.0%、24.6%和13.0%。
- 该指标可用于非酒精性脂肪性肝炎早期试验的样本量估算。
核心结论
- MRI-PDFF相对下降≥30%是NAFLD患者纤维化逆转≥1期的独立预测因子,校正OR为6.46(95%CI 1.1-37.0,p=0.04)。
- 早期试验中MRI-PDFF相对下降≥30%可提供纤维化改善几率的有效估计,有助于非酒精性脂肪性肝炎试验的样本量估算。
研究设计与样本
- 前瞻性研究,纳入100例经活检证实NAFLD且有两个时间点配对同期MRI-PDFF评估的充分表征患者。
- MRI-PDFF应答定义为MRI-PDFF相对下降≥30%,主要结局为组织学纤维化逆转≥1期。
主要发现
- 中位(IQR)年龄54(43-62)岁,BMI 31.9(29-36)kg/m2。
- 多变量校正逻辑回归(校正年龄、性别、糖尿病状态、种族/民族、活检间隔、γ-谷氨酰转移酶、磁共振弹性成像肝硬度及血小板计数变化)显示MRI-PDFF应答为纤维化逆转的独立预测因子,校正OR 6.46(95%CI 1.1-37.0,p=0.04)。
- MRI-PDFF应答患者中纤维化逆转、纤维化无变化和纤维化进展的比例分别为40.0%、24.6%和13.0%,且MRI-PDFF应答患者比例随纤维化逆转而增加(p=0.03)。
临床怎么用
- 在NAFLD早期临床试验中,可将MRI-PDFF相对下降≥30%作为估计纤维化逆转几率的指标。
- 该数据可用于非酒精性脂肪性肝炎试验的样本量估算。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Emerging data suggest that a 30% relative decline in liver fat, as assessed by MRI-proton density fat fraction (MRI-PDFF), may be associated with Non-Alcoholic Fatty Liver Disease Activity Score improvement, but the association between decline in MRI-PDFF and fibrosis regression is not known. Therefore, we aimed to examine the association between ≥30% relative decline in MRI-PDFF and fibrosis regression in non-alcoholic fatty liver disease (NAFLD). DESIGN: This prospective study included 100 well-characterised patients with biopsy-proven NAFLD with paired contemporaneous MRI-PDFF assessment at two time points. MRI-PDFF response was defined as ≥30% relative decline in MRI-PDFF. The primary outcome was ≥1 stage histological fibrosis regression. RESULTS: The median (IQR) age was 54 (43-62) years and body mass index was 31.9 (29-36) kg/m2. In multivariable-adjusted logistic regression analysis (adjusted for age, gender, diabetes status, race/ethnicity, interval between biopsies, gamma-glutamyl transferase, liver stiffness by magnetic resonance elastography and change in platelet counts), MRI-PDFF response was an independent predictor of fibrosis regression with an adjusted OR of 6.46 (95% CI 1.1 to 37.0, p=0.04). The proportion of patients with MRI-PDFF response with fibrosis regression, no change in fibrosis and fibrosis progression was 40.0%, 24.6% and 13.0%, respectively, and the proportion of patients with MRI-PDFF response increased with fibrosis regression (p=0.03). CONCLUSION: ≥30% reduction in MRI-PDFF in early phase trials can provide a useful estimate of odds of ≥1 stage improvement in fibrosis. These data may be helpful in sample size estimation in non-alcoholic steatohepatitis trials.
引用
- Tamaki N, Munaganuru N, Jung J, et al. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. Gut. 2021. PMID: 33883248. doi:10.1136/gutjnl-2021-324264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。